Beyond body-weight loss and systemic IFNγ release, IL-18mutE2-treated animals also showed visible signs of systemic inflammation, including splenomegaly, hepatomegaly, hunched posture, ruffled fur, reduced food and water intake, and lethargy. The gene discussed is IFNG; the disease is Splenomegaly.